{"id":43647,"date":"2022-07-02T12:30:15","date_gmt":"2022-07-02T16:30:15","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=43647"},"modified":"2022-07-02T12:37:07","modified_gmt":"2022-07-02T16:37:07","slug":"infographic-biotech-index-continues-decline-in-q2","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=43647","title":{"rendered":"Infographic – Biotech Index Continues Decline in Q2"},"content":{"rendered":"
\"Nasdaq<\/a>
Click on image for full-size view (Wall Street Journal)<\/figcaption><\/figure>\n

2 July 2022. A new look at the Nasdaq Biotechnology Index<\/a> shows investors’ chill in biotech stocks begun earlier in the year continued into the second quarter of 2022. So far this year, NBI fell by 29 percent from the opening bell on 3 Jan., mirroring a similar decline in the Nasdaq Composite Index, an indicator of investor sentiment in technology stocks overall.<\/p>\n

Nasdaq calculates NBI from share prices of 369 biotech and pharma companies<\/a> publicly traded on its exchange. As we saw in our first quarter review<\/a>, the index opened the year at 4728 and almost immediately began falling through mid-March. By the end of Q1, NBI fell about 12 percent for the year, and continued declining until 11 May, when it reached 3382, the low so far this year. Since mid-May, NBI rebounded somewhat to 3749, ending the first six months of 2022 with a decline of 29 percent.<\/p>\n

The technology sector overall is taking a beating from investors this year. The Nasdaq Composite Index<\/a>, representing a cross-section of technology stocks is also down 29 percent since the beginning of 2022. In the first quarter of the year, NBI performed a little better than the Composite Index, but now the rates of decline are almost identical.<\/p>\n

More from Science & Enterprise:<\/p>\n